

500. 7/9
09/899917

=> dis his

(FILE 'HOME' ENTERED AT 17:05:56 ON 10 JAN 2003)

FILE 'BIOSIS, CAPLUS, EMBASE, MEDLINE, SCISEARCH' ENTERED AT 17:08:26 ON
10 JAN 2003

L1	2 S HUMAN (W) ONCOGENE (W) INDUCED (W) SECRET? (W) PROTEIN
L2	2 S HOIPS OR HOIPSI
L3	2 L1 AND L2
L4	2 L3 AND (POLYPEPTIDE OR PROTEIN OR FRAGMENT OR MUTANT)
L5	2 DUP REM L1 (0 DUPLICATES REMOVED)
L6	2 DUP REM L2 (0 DUPLICATES REMOVED)
L7	2 DUP REM L3 (0 DUPLICATES REMOVED)
L8	2 DUP REM L4 (0 DUPLICATES REMOVED)

=> log off y

STN INTERNATIONAL LOGOFF AT 17:19:05 ON 10 JAN 2003

STN Search Strategy

File Copy
09/899917
EAST Search Strategy

Type	L #	Hits	Search Text	DBs	Time Stamp	Comments	Error Definition	Errors
1	BRS L7	32213 70	HOIPS or HOIPS I	USPA T; US-P GPUB ; EPO; JPO; DERW ENT	2003/01/1 0 16:18			0
2	BRS L26	5	L1 and (polypeptide or protein or fragment or mutant)	USPA T; US-P GPUB ; EPO; JPO; DERW ENT	2003/01/1 0 16:25			0
3	BRS L20	4	L1 and L13	USPA T; US-P GPUB ; EPO; JPO; DERW ENT	2003/01/1 0 16:27			0
4	BRS L13	4	HOIPS	USPA T; US-P GPUB ; EPO; JPO; DERW ENT	2003/01/1 0 16:29			0

	Type	L #	Hits	Search Text	DBs	Time Stamp	Comments	Error Definition	Errors
5	BRS	L1	5	human adj oncogene adj induced adj secret\$ adj protein	USPA T; US-P GPUB ; EPO; JPO; DERW ENT	2003/01/10 16:30			0

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal653hxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	Jun 03	New e-mail delivery for search results now available
NEWS	4	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS	5	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS	6	Aug 26	Sequence searching in REGISTRY enhanced
NEWS	7	Sep 03	JAPIO has been reloaded and enhanced
NEWS	8	Sep 16	Experimental properties added to the REGISTRY file
NEWS	9	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS	10	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS	11	Oct 24	BEILSTEIN adds new search fields
NEWS	12	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS	13	Nov 18	DKILIT has been renamed APOLLIT
NEWS	14	Nov 25	More calculated properties added to REGISTRY
NEWS	15	Dec 04	CSA files on STN
NEWS	16	Dec 17	PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS	17	Dec 17	TOXCENTER enhanced with additional content
NEWS	18	Dec 17	Adis Clinical Trials Insight now available on STN
NEWS	19	Jan 29	Simultaneous left and right truncation added to COMPENDEX, ENERGY, INSPEC
NEWS	20	Feb 13	CANCERLIT is no longer being updated
NEWS	21	Feb 24	METADEX enhancements
NEWS	22	Feb 24	PCTGEN now available on STN
NEWS	23	Feb 24	TEMA now available on STN
NEWS	24	Feb 26	NTIS now allows simultaneous left and right truncation
NEWS	25	Feb 26	PCTFULL now contains images
NEWS	26	Mar 04	SDI PACKAGE for monthly delivery of multifile SDI results
NEWS	27	Mar 20	EVENTLINE will be removed from STN
NEWS	28	Mar 24	PATDPAFULL now available on STN
NEWS	29	Mar 24	Additional information for trade-named substances without structures available in REGISTRY
NEWS	30	Apr 11	Display formats in DGENE enhanced
NEWS	31	Apr 14	MEDLINE Reload
NEWS	32	Apr 17	Polymer searching in REGISTRY enhanced
NEWS	33	Jun 13	Indexing from 1947 to 1956 added to records in CA/CAPLUS
NEWS	34	Apr 21	New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX
NEWS	35	Apr 28	RDISCLOSURE now available on STN
NEWS	36	May 05	Pharmacokinetic information and systematic chemical names added to PHAR
NEWS	37	May 15	MEDLINE file segment of TOXCENTER reloaded
NEWS	38	May 15	Supporter information for ENCOMPPAT and ENCOMPLIT updated
NEWS	39	May 16	CHEMREACT will be removed from STN
NEWS	40	May 19	Simultaneous left and right truncation added to WSCA
NEWS	41	May 19	RAPRA enhanced with new search field, simultaneous left and right truncation
NEWS	42	Jun 06	Simultaneous left and right truncation added to CBNB

NEWS 43 Jun 06 PASCAL enhanced with additional data
NEWS 44 Jun 20 2003 edition of the FSTA Thesaurus is now available
NEWS 45 Jun 25 HSDB has been reloaded

NEWS EXPRESS April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT
MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 12:38:50 ON 30 JUN 2003

=> file medline, biosis, wpids, embase, dgene, uspatful
COST IN U.S. DOLLARS SINCE FILE TOTAL
 ENTRY SESSION
FULL ESTIMATED COST 0.21 0.21

FILE 'MEDLINE' ENTERED AT 12:39:27 ON 30 JUN 2003

FILE 'BIOSIS' ENTERED AT 12:39:27 ON 30 JUN 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'WPIDS' ENTERED AT 12:39:27 ON 30 JUN 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'EMBASE' ENTERED AT 12:39:27 ON 30 JUN 2003
COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

FILE 'DGENE' ENTERED AT 12:39:27 ON 30 JUN 2003
COPYRIGHT (C) 2003 DERWENT INFORMATION LTD

FILE 'USPATFULL' ENTERED AT 12:39:27 ON 30 JUN 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

=> s human oncogene induced secreted protein
5 FILES SEARCHED...
L1 21 HUMAN ONCOGENE INDUCED SECRETED PROTEIN

=> d l1 ti abs ibib tot

L1 ANSWER 1 OF 21 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.

TI **Human oncogene induced secreted protein I.**

AB The present invention relates to a novel protein, the **Human Oncogene Induced Secreted Protein I** ("HOIPS I") protein. In particular, isolated nucleic acid molecules are provided encoding the human HOIPS I protein. HOIPS I polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. Also provided are diagnostic methods for detecting abnormal cell proliferation and differentiation disorders and therapeutic methods for

treating the same.

ACCESSION NUMBER: 2001:519304 BIOSIS
DOCUMENT NUMBER: PREV200100519304
TITLE: **Human oncogene induced secreted protein I.**
AUTHOR(S): Olsen, Henrik S.; Ruben, Steven M.
ASSIGNEE: Human Genome Sciences, Inc.
PATENT INFORMATION: US 6284486 September 04, 2001
SOURCE: Official Gazette of the United States Patent and Trademark Office Patents, (Sep. 4, 2001) Vol. 1250, No. 1, pp. No
Pagination. e-file.
ISSN: 0098-1133.
DOCUMENT TYPE: Patent
LANGUAGE: English

L1 ANSWER 2 OF 21 WPIDS (C) 2003 THOMSON DERWENT

TI New isolated **human oncogene induced secreted protein** - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia.

AN 1998-377652 [32] WPIDS

AB WO 9828421 A UPAB: 19980812

An isolated nucleic acid molecule (I) is claimed comprising a polynucleotide (PN) having a nucleotide sequence (NS) at least 95% identical to a sequence selected from:

(a) a NS encoding a polypeptide comprising amino acids from -20 to 142, -19 to 142, or 1 to 142 of the 162 amino acid (aa) sequence given in the specification (sequence representing a **Human Oncogene Induced Secreted Protein I** (HOIPS I) polypeptide);

(b) a NS encoding a polypeptide having an amino acid sequence encoded by a cDNA clone contained in ATCC 97825;

(c) a NS encoding a mature HOIPS I polypeptide having an amino acid sequence encoded by a cDNA clone contained in ATCC 97825; and

(d) a NS complementary to any of the NSs in (a)-(c).

Also claimed are:

(1) an isolated Nucleic Acid Molecule (NAM) comprising a PN which hybridises under stringent hybridisation conditions (I) where the PN which hybridises does not hybridise under stringent hybridisation conditions to a PN having a NS consisting of only A residues or of only T residues;

(2) an isolated NAM comprising a PN which encodes an amino acid sequence of an epitope-bearing portion of a HOIPS I polypeptide having an amino acid sequence as in (a)-(c) above;

(3) an isolated NAM comprising a PN having a sequence at least 95% identical to a sequence selected from:

(a) a NS of a fragment of a 860 bp sequence given in the specification (encoding the HOIPS I polypeptide), where the fragment comprises at least 50 contiguous nucleotides of the 860 bp, provided that the NS is not one of the 514, 457, 413, 320, 264, and 249 sequences given in the specification; and

(b) a NS complementary to a NS as in (a);

(4) a method for making a recombinant vector comprising inserting (I) into a vector;

(5) a recombinant vector produced by a method as in (4);

(6) a method of making a recombinant host cell comprising introducing a recombinant vector as in (5) into a host cell;

(7) a recombinant host cell produced by a method as in (6);

(8) an isolated HOIPS I polypeptide having an amino acid sequence at least 95% identical to a sequence encoded by (I) or an epitope-bearing portion of the polypeptide;

(9) an isolated polypeptide comprising an epitope-bearing portion of the HOIPS I protein, where the portion is selected from a polypeptide comprising amino acid residues from -4 to 9, from 13 to 19, from 23 to 32, from 36 to 47, from 54 to 63, from 70 to 74, from 90 to 100, from 105 to

119 or from 125 to 132 of the 162 aa sequence;

(10) an isolated HOIPS I polypeptide where, except for 1 to 50 conservative amino acid substitutions, the polypeptide has a sequence selected from:

(a) amino acids from -20 to 142, 19 to 142, or 1 to 142 of the 162 aa sequence given in the specification;

(b) an amino acid sequence of the HOIPS I polypeptide having an amino acid sequence encoded by a cDNA contained in ATCC 97825;

(c) an amino acid sequence of a mature HOIPS I polypeptide having an amino acid sequence encoded by a cDNA clone contained in ATCC 97825; and

(d) an amino acid sequence of an epitope-bearing portion of any one of the polypeptides as in (a)-(c);

(11) an isolated nucleic acid encoding a polypeptide as in (10).

USE - The products can be used for treating cell proliferative diseases, particularly cancers, such as acute and chronic myelogenous leukaemias. The products can also be used for detection and diagnosis.

Dwg.0/3

ACCESSION NUMBER: 1998-377652 [32] WPIDS
DOC. NO. NON-CPI: N1998-295209
DOC. NO. CPI: C1998-114764
TITLE: New isolated **human oncogene induced secreted protein** -
used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia.
DERWENT CLASS: B04 D16 S03
INVENTOR(S): OLSEN, H S; RUBEN, S M
PATENT ASSIGNEE(S): (HUMA-N) HUMAN GENOME SCI INC
COUNTRY COUNT: 81
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 9828421	A1	19980702	(199832)*	EN	71
RW: AT BE CH DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SZ UG ZW					
W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW					
AU 9858027	A	19980717	(199848)		
US 6284486	B1	20010904	(200154)		
US 2002119552	A1	20020829	(200259)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 9828421	A1	WO 1997-US23547	19971219
AU 9858027	A	AU 1998-58027	19971219
US 6284486	B1	US 1996-33869P	19961220
	Provisional	US 1997-37388P	19970207
		US 1997-994962	19971219
US 2002119552	A1	US 1996-33869P	19961220
	Provisional	US 1997-37388P	19970207
	Div ex	US 1997-994962	19971219
		US 2001-899917	20010709

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 9858027	A Based on	WO 9828421

PRIORITY APPLN. INFO: US 1997-37388P 19970207; US 1996-33869P
19961220; US 1997-994962 19971219; US
2001-899917 20010709

L1 ANSWER 3 OF 21 DGENE (C) 2003 THOMSON DERWENT

TI New isolated **human oncogene induced secreted protein** - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia

AN AAW69220 Protein DGENE

AB This sequence is the **human oncogene induced secreted protein I** (HOIPS I) of the invention. HOIPS I can be used for treating cell proliferative diseases, particularly cancers, such as acute and chronic myelogenous leukaemias. The products can also be used for detection and diagnosis of a cell proliferative or cell differentiation disorders.

ACCESSION NUMBER: AAW69220 Protein DGENE

TITLE: New isolated **human oncogene induced secreted protein** - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia

INVENTOR: Olsen H S; Ruben S M

PATENT ASSIGNEE: (HUMA-N)HUMAN GENOME SCI INC.

PATENT INFO: WO 9828421 A1 19980702 71p

APPLICATION INFO: WO 1997-US23547 19971219

PRIORITY INFO: US 1997-37388 19970207

US 1996-33869 19961220

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 1998-377652 [32]

CROSS REFERENCES: N-PSDB: AAV44745

DESCRIPTION: **Human oncogene induced secreted protein I.**

L1 ANSWER 4 OF 21 DGENE (C) 2003 THOMSON DERWENT

TI New isolated **human oncogene induced secreted protein** - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia

AN AAV44751 cDNA DGENE

AB This sequence represents an expressed sequence tag, which is specifically stated as not being contained within the DNA of the invention. The DNA of the invention encodes the **human oncogene induced secreted protein I** (HOIPS I). HOIPS I can be used for treating cell proliferative diseases, particularly cancers, such as acute and chronic myelogenous leukaemias. The products can also be used for detection and diagnosis of a cell proliferative or cell differentiation disorders.

ACCESSION NUMBER: AAV44751 cDNA DGENE

TITLE: New isolated **human oncogene induced secreted protein** - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia

INVENTOR: Olsen H S; Ruben S M

PATENT ASSIGNEE: (HUMA-N)HUMAN GENOME SCI INC.

PATENT INFO: WO 9828421 A1 19980702 71p

APPLICATION INFO: WO 1997-US23547 19971219

PRIORITY INFO: US 1997-37388 19970207

US 1996-33869 19961220

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 1998-377652 [32]

DESCRIPTION: Expressed sequence tag C02431.

L1 ANSWER 5 OF 21 DGENE (C) 2003 THOMSON DERWENT
TI New isolated **human oncogene induced secreted protein** - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia
AN AAV44750 cDNA DGENE
AB This sequence represents an expressed sequence tag, which is specifically stated as not being contained within the DNA of the invention. The DNA of the invention encodes the **human oncogene induced secreted protein I** (HOIPS I). HOIPS I can be used for treating cell proliferative diseases, particularly cancers, such as acute and chronic myelogenous leukaemias. The products can also be used for detection and diagnosis of a cell proliferative or cell differentiation disorders.

ACCESSION NUMBER: AAV44750 cDNA DGENE
TITLE: New isolated **human oncogene induced secreted protein** - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia
INVENTOR: Olsen H S; Ruben S M
PATENT ASSIGNEE: (HUMA-N)HUMAN GENOME SCI INC.
PATENT INFO: WO 9828421 A1 19980702 71p
APPLICATION INFO: WO 1997-US23547 19971219
PRIORITY INFO: US 1997-37388 19970207
US 1996-33869 19961220
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 1998-377652 [32]
DESCRIPTION: Expressed sequence tag T84854.

L1 ANSWER 6 OF 21 DGENE (C) 2003 THOMSON DERWENT
TI New isolated **human oncogene induced secreted protein** - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia
AN AAV44749 cDNA DGENE
AB This sequence represents an expressed sequence tag, which is specifically stated as not being contained within the DNA of the invention. The DNA of the invention encodes the **human oncogene induced secreted protein I** (HOIPS I). HOIPS I can be used for treating cell proliferative diseases, particularly cancers, such as acute and chronic myelogenous leukaemias. The products can also be used for detection and diagnosis of a cell proliferative or cell differentiation disorders.

ACCESSION NUMBER: AAV44749 cDNA DGENE
TITLE: New isolated **human oncogene induced secreted protein** - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia
INVENTOR: Olsen H S; Ruben S M
PATENT ASSIGNEE: (HUMA-N)HUMAN GENOME SCI INC.
PATENT INFO: WO 9828421 A1 19980702 71p
APPLICATION INFO: WO 1997-US23547 19971219
PRIORITY INFO: US 1997-37388 19970207
US 1996-33869 19961220
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 1998-377652 [32]
DESCRIPTION: Expressed sequence tag T92475.

L1 ANSWER 7 OF 21 DGENE (C) 2003 THOMSON DERWENT
 TI New isolated **human oncogene induced secreted protein** - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia
 AN AAV44748 cDNA DGENE
 AB This sequence represents an expressed sequence tag, which is specifically stated as not being contained within the DNA of the invention. The DNA of the invention encodes the **human oncogene induced secreted protein I** (HOIPS I). HOIPS I can be used for treating cell proliferative diseases, particularly cancers, such as acute and chronic myelogenous leukaemias. The products can also be used for detection and diagnosis of a cell proliferative or cell differentiation disorders.

ACCESSION NUMBER: AAV44748 cDNA DGENE
 TITLE: New isolated **human oncogene induced secreted protein** - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia

INVENTOR: Olsen H S; Ruben S M
 PATENT ASSIGNEE: (HUMA-N)HUMAN GENOME SCI INC.
 PATENT INFO: WO 9828421 A1 19980702 71p
 APPLICATION INFO: WO 1997-US23547 19971219
 PRIORITY INFO: US 1997-37388 19970207
 US 1996-33869 19961220

DOCUMENT TYPE: Patent
 LANGUAGE: English
 OTHER SOURCE: 1998-377652 [32]
 DESCRIPTION: Expressed sequence tag T91708.

L1 ANSWER 8 OF 21 DGENE (C) 2003 THOMSON DERWENT
 TI New isolated **human oncogene induced secreted protein** - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia
 AN AAV44758 DNA DGENE
 AB This sequence is a PCR primer for DNA encoding the **human oncogene induced secreted protein I** (HOIPS I) of the invention. HOIPS I can be used for treating cell proliferative diseases, particularly cancers, such as acute and chronic myelogenous leukaemias. The products can also be used for detection and diagnosis of a cell proliferative or cell differentiation disorders.

ACCESSION NUMBER: AAV44758 DNA DGENE
 TITLE: New isolated **human oncogene induced secreted protein** - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia

INVENTOR: Olsen H S; Ruben S M
 PATENT ASSIGNEE: (HUMA-N)HUMAN GENOME SCI INC.
 PATENT INFO: WO 9828421 A1 19980702 71p
 APPLICATION INFO: WO 1997-US23547 19971219
 PRIORITY INFO: US 1997-37388 19970207
 US 1996-33869 19961220

DOCUMENT TYPE: Patent
 LANGUAGE: English
 OTHER SOURCE: 1998-377652 [32]
 DESCRIPTION: Primer for **Human oncogene induced secreted protein I**.

L1 ANSWER 9 OF 21 DGENE (C) 2003 THOMSON DERWENT
 TI New isolated **human oncogene induced secreted protein** - used to develop products for the

diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia

AN AAV44757 DNA DGENE
AB This sequence is a PCR primer for DNA encoding the **human oncogene induced secreted protein I** (HOIPS I) of the invention. HOIPS I can be used for treating cell proliferative diseases, particularly cancers, such as acute and chronic myelogenous leukaemias. The products can also be used for detection and diagnosis of a cell proliferative or cell differentiation disorders.

ACCESSION NUMBER: AAV44757 DNA DGENE
TITLE: New isolated **human oncogene induced secreted protein** - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia
INVENTOR: Olsen H S; Ruben S M
PATENT ASSIGNEE: (HUMA-N)HUMAN GENOME SCI INC.
PATENT INFO: WO 9828421 A1 19980702 71p
APPLICATION INFO: WO 1997-US23547 19971219
PRIORITY INFO: US 1997-37388 19970207
US 1996-33869 19961220
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 1998-377652 [32]
DESCRIPTION: Primer for **Human oncogene induced secreted protein I**.

L1 ANSWER 10 OF 21 DGENE (C) 2003 THOMSON DERWENT

TI New isolated **human oncogene induced secreted protein** - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia

AN AAV44756 DNA DGENE
AB This sequence is a PCR primer for DNA encoding the **human oncogene induced secreted protein I** (HOIPS I) of the invention. HOIPS I can be used for treating cell proliferative diseases, particularly cancers, such as acute and chronic myelogenous leukaemias. The products can also be used for detection and diagnosis of a cell proliferative or cell differentiation disorders.

ACCESSION NUMBER: AAV44756 DNA DGENE
TITLE: New isolated **human oncogene induced secreted protein** - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia
INVENTOR: Olsen H S; Ruben S M
PATENT ASSIGNEE: (HUMA-N)HUMAN GENOME SCI INC.
PATENT INFO: WO 9828421 A1 19980702 71p
APPLICATION INFO: WO 1997-US23547 19971219
PRIORITY INFO: US 1997-37388 19970207
US 1996-33869 19961220
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 1998-377652 [32]
DESCRIPTION: Primer for **Human oncogene induced secreted protein I**.

L1 ANSWER 11 OF 21 DGENE (C) 2003 THOMSON DERWENT

TI New isolated **human oncogene induced secreted protein** - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia

AN AAV44755 DNA DGENE
AB This sequence is a PCR primer for DNA encoding the **human**

oncogene induced secreted protein I

(HOIPS I) of the invention. HOIPS I can be used for treating cell proliferative diseases, particularly cancers, such as acute and chronic myelogenous leukaemias. The products can also be used for detection and diagnosis of a cell proliferative or cell differentiation disorders.

ACCESSION NUMBER: AAV44755 DNA DGENE

TITLE: New isolated **human oncogene induced secreted protein** - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia

INVENTOR: Olsen H S; Ruben S M

PATENT ASSIGNEE: (HUMA-N)HUMAN GENOME SCI INC.

PATENT INFO: WO 9828421 A1 19980702 71p

APPLICATION INFO: WO 1997-US23547 19971219

PRIORITY INFO: US 1997-37388 19970207

US 1996-33869 19961220

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 1998-377652 [32]

DESCRIPTION: Primer for **Human oncogene induced secreted protein I**.

L1 ANSWER 12 OF 21 DGENE (C) 2003 THOMSON DERWENT

TI New isolated **human oncogene induced secreted protein** - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia

AN AAV44754 DNA DGENE

AB This sequence is a PCR primer for DNA encoding the **human oncogene induced secreted protein I** (HOIPS I) of the invention. HOIPS I can be used for treating cell proliferative diseases, particularly cancers, such as acute and chronic myelogenous leukaemias. The products can also be used for detection and diagnosis of a cell proliferative or cell differentiation disorders.

ACCESSION NUMBER: AAV44754 DNA DGENE

TITLE: New isolated **human oncogene induced secreted protein** - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia

INVENTOR: Olsen H S; Ruben S M

PATENT ASSIGNEE: (HUMA-N)HUMAN GENOME SCI INC.

PATENT INFO: WO 9828421 A1 19980702 71p

APPLICATION INFO: WO 1997-US23547 19971219

PRIORITY INFO: US 1997-37388 19970207

US 1996-33869 19961220

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 1998-377652 [32]

DESCRIPTION: Primer for **Human oncogene induced secreted protein I**.

L1 ANSWER 13 OF 21 DGENE (C) 2003 THOMSON DERWENT

TI New isolated **human oncogene induced secreted protein** - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia

AN AAV44753 DNA DGENE

AB This sequence is a PCR primer for DNA encoding the **human oncogene induced secreted protein I** (HOIPS I) of the invention. HOIPS I can be used for treating cell proliferative diseases, particularly cancers, such as acute and chronic myelogenous leukaemias. The products can also be used for detection and

diagnosis of a cell proliferative or cell differentiation disorders.

ACCESSION NUMBER: AAV44753 DNA DGENE
TITLE: New isolated **human oncogene induced secreted protein** - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia
INVENTOR: Olsen H S; Ruben S M
PATENT ASSIGNEE: (HUMA-N)HUMAN GENOME SCI INC.
PATENT INFO: WO 9828421 A1 19980702 71p
APPLICATION INFO: WO 1997-US23547 19971219
PRIORITY INFO: US 1997-37388 19970207
US 1996-33869 19961220
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 1998-377652 [32]
DESCRIPTION: Primer for **Human oncogene induced secreted protein I**.

L1 ANSWER 14 OF 21 DGENE (C) 2003 THOMSON DERWENT
TI New isolated **human oncogene induced secreted protein** - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia
AN AAV44752 DNA DGENE
AB This sequence is a PCR primer for DNA encoding the **human oncogene induced secreted protein I** (HOIPS I) of the invention. HOIPS I can be used for treating cell proliferative diseases, particularly cancers, such as acute and chronic myelogenous leukaemias. The products can also be used for detection and diagnosis of a cell proliferative or cell differentiation disorders.

ACCESSION NUMBER: AAV44752 DNA DGENE
TITLE: New isolated **human oncogene induced secreted protein** - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia
INVENTOR: Olsen H S; Ruben S M
PATENT ASSIGNEE: (HUMA-N)HUMAN GENOME SCI INC.
PATENT INFO: WO 9828421 A1 19980702 71p
APPLICATION INFO: WO 1997-US23547 19971219
PRIORITY INFO: US 1997-37388 19970207
US 1996-33869 19961220
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 1998-377652 [32]
DESCRIPTION: Primer for **Human oncogene induced secreted protein I**.

L1 ANSWER 15 OF 21 DGENE (C) 2003 THOMSON DERWENT
TI New isolated **human oncogene induced secreted protein** - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia
AN AAV44746 cDNA DGENE
AB This sequence represents an expressed sequence tag, which is specifically stated as not being contained within the DNA of the invention. The DNA of the invention encodes the **human oncogene induced secreted protein I** (HOIPS I). HOIPS I can be used for treating cell proliferative diseases, particularly cancers, such as acute and chronic myelogenous leukaemias. The products can also be used for detection and diagnosis of a cell proliferative or cell differentiation disorders.
ACCESSION NUMBER: AAV44746 cDNA DGENE

TITLE: New isolated **human oncogene induced secreted protein** - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia

INVENTOR: Olsen H S; Ruben S M

PATENT ASSIGNEE: (HUMA-N)HUMAN GENOME SCI INC.

PATENT INFO: WO 9828421 A1 19980702 71p

APPLICATION INFO: WO 1997-US23547 19971219

PRIORITY INFO: US 1997-37388 19970207

US 1996-33869 19961220

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 1998-377652 [32]

DESCRIPTION: Expressed sequence tag.

L1 ANSWER 16 OF 21 DGENE (C) 2003 THOMSON DERWENT

TI New isolated **human oncogene induced secreted protein** - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia

AN AAV44747 cDNA DGENE

AB This sequence represents an expressed sequence tag, which is specifically stated as not being contained within the DNA of the invention. The DNA of the invention encodes the **human oncogene induced secreted protein I** (HOIPS I). HOIPS I can be used for treating cell proliferative diseases, particularly cancers, such as acute and chronic myelogenous leukaemias. The products can also be used for detection and diagnosis of a cell proliferative or cell differentiation disorders.

ACCESSION NUMBER: AAV44747 cDNA DGENE

TITLE: New isolated **human oncogene induced secreted protein** - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia

INVENTOR: Olsen H S; Ruben S M

PATENT ASSIGNEE: (HUMA-N)HUMAN GENOME SCI INC.

PATENT INFO: WO 9828421 A1 19980702 71p

APPLICATION INFO: WO 1997-US23547 19971219

PRIORITY INFO: US 1997-37388 19970207

US 1996-33869 19961220

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 1998-377652 [32]

DESCRIPTION: Expressed sequence tag AA340310.

L1 ANSWER 17 OF 21 DGENE (C) 2003 THOMSON DERWENT

TI New isolated **human oncogene induced secreted protein** - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia

AN AAV44745 cDNA DGENE

AB This sequence encodes the **human oncogene induced secreted protein I** (HOIPS I) of the invention. HOIPS I can be used for treating cell proliferative diseases, particularly cancers, such as acute and chronic myelogenous leukaemias. The products can also be used for detection and diagnosis of a cell proliferative or cell differentiation disorders.

ACCESSION NUMBER: AAV44745 cDNA DGENE

TITLE: New isolated **human oncogene induced secreted protein** - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as

leukaemia

INVENTOR: Olsen H S; Ruben S M

PATENT ASSIGNEE: (HUMA-N)HUMAN GENOME SCI INC.

PATENT INFO: WO 9828421 A1 19980702 71p

APPLICATION INFO: WO 1997-US23547 19971219

PRIORITY INFO: US 1997-37388 19970207

US 1996-33869 19961220

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 1998-377652 [32]

CROSS REFERENCES: P-PSDB: AAW69220

DESCRIPTION: **Human oncogene induced secreted protein I** coding sequence.

L1 ANSWER 18 OF 21 USPATFULL

TI Method and system for providing real-time, in situ biomanufacturing process monitoring and control in response to IR spectroscopy

AB A method and system for providing real-time, biomanufacturing process monitoring and control in response to infra-red (IR) spectroscopic fingerprinting of a biomolecule. IR spectroscopy is used to fingerprint an active biomolecule in situ in a biomanufacturing process. In one embodiment, Fourier Transform Infra-red spectroscopy (FTIR) is used to determine whether an active or aged biomolecule is present in stages of a biomanufacturing process. In one preferred example, the biomanufacturing process manufactures a biomaterial in bulk. The biomanufacturing process has four stages: bioproduction, recovery, purification, and bulk storage. FTIR spectroscopy is used to monitor the optimization of each process step by providing feedback controls, and to fingerprint in real-time, in situ whether active biomolecules are present in each stage.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:280105 USPATFULL

TITLE: Method and system for providing real-time, in situ biomanufacturing process monitoring and control in response to IR spectroscopy

INVENTOR(S): Naughton, Raymond A., West River, MD, UNITED STATES
Rohrer, Thomas R., Hagerstown, MD, UNITED STATES
Gentz, Reiner L., Rockville, MD, UNITED STATES

PATENT ASSIGNEE(S): Human Genome Sciences, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002155541	A1	20021024
APPLICATION INFO.:	US 2002-114469	A1	20020403 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2000-616894, filed on 14 Jul 2000, GRANTED, Pat. No. US 6395538		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-157863P	19991006 (60)
	US 1999-151918P	19990901 (60)
	US 1999-144071P	19990716 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C., 1100 NEW YORK AVENUE, N.W., SUITE 600, WASHINGTON, DC, 20005-3934	

NUMBER OF CLAIMS: 38

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 13 Drawing Page(s)

LINE COUNT: 2291

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 19 OF 21 USPATFULL

TI **Human oncogene induced secreted protein I**

AB The present invention relates to a novel protein, the **Human Oncogene Induced Secreted Protein I** ("HOIPS I") protein. In particular, isolated nucleic acid molecules are provided encoding the human HOIPS I protein. HOIPS I polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. Also provided are diagnostic methods for detecting abnormal cell proliferation and differentiation disorders and therapeutic methods for treating the same.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:221411 USPATFULL

TITLE: **Human oncogene induced secreted protein I**

INVENTOR(S): Olsen, Henrik S., Gaithersburg, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES

PATENT ASSIGNEE(S): Human Genome Sciences, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002119552	A1	20020829
APPLICATION INFO.:	US 2001-899917	A1	20010709 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1997-994962, filed on 19 Dec 1997, PATENTED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-33869P	19961220 (60)
	US 1997-37388P	19970207 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C., 1100 NEW YORK AVENUE, N.W., SUITE 600, WASHINGTON, DC, 20005-3934	
NUMBER OF CLAIMS:	16	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	4 Drawing Page(s)	
LINE COUNT:	2059	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 20 OF 21 USPATFULL

TI Method and system for providing real-time, in situ biomanufacturing process monitoring and control in response to IR spectroscopy

AB A method and system for providing real-time, biomanufacturing process monitoring and control in response to infra-red (IR) spectroscopic fingerprinting of a biomolecule. IR spectroscopy is used to fingerprint an active biomolecule in situ in a biomanufacturing process. In one embodiment, Fourier Transform Infra-red spectroscopy (FTIR) is used to determine whether an active or aged biomolecule is present in stages of a biomanufacturing process. In one preferred example, the biomanufacturing process manufactures a biomaterial in bulk. The biomanufacturing process has four stages: bioproduction, recovery, purification, and bulk storage. FTIR spectroscopy is used to monitor the optimization of each process step by providing feedback controls, and to fingerprint in real-time, in situ whether active biomolecules are present in each stage.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:122481 USPATFULL

TITLE: Method and system for providing real-time, in situ biomanufacturing process monitoring and control in response to IR spectroscopy

INVENTOR(S): Naughton, Raymond A., West River, MD, United States
Rohrer, Thomas R., Hagerstown, MD, United States
Gentz, Reiner L., Rockville, MD, United States
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6395538	B1	20020528
APPLICATION INFO.:	US 2000-616894		20000714 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-157863P	19991006 (60)
	US 1999-144071P	19990716 (60)
	US 1999-151918P	19990901 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Weber, Jon P.
LEGAL REPRESENTATIVE: Sterne, Kessler, Goldstein & Fox P.L.L.C.
NUMBER OF CLAIMS: 27
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 13 Drawing Figure(s); 13 Drawing Page(s)
LINE COUNT: 2209
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 21 OF 21 USPATFULL

TI **Human oncogene induced secreted protein I**

AB The present invention relates to a novel protein, the **Human Oncogene Induced Secreted Protein I** ("HOIPS I") protein. In particular, isolated nucleic acid molecules are provided encoding the human HOIPS I protein. HOIPS I polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. Also provided are diagnostic methods for detecting abnormal cell proliferation and differentiation disorders and therapeutic methods for treating the same.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:147697 USPATFULL

TITLE: **Human oncogene induced secreted protein I**

INVENTOR(S): Olsen, Henrik S., Gaithersburg, MD, United States
Ruben, Steven M., Olney, MD, United States

PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6284486	B1	20010904
APPLICATION INFO.:	US 1997-994962		19971219 (8)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Carlson, Karen Cochrane
LEGAL REPRESENTATIVE: Sterne, Kessler, Goldstein & Fox P.L.L.C.
NUMBER OF CLAIMS: 69
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 1994
CAS INDEXING IS AVAILABLE FOR THIS PATENT.